Intravenous immunoglobulin in critically ill adults: When and what is the evidence?
Identifieur interne : 002C18 ( Main/Exploration ); précédent : 002C17; suivant : 002C19Intravenous immunoglobulin in critically ill adults: When and what is the evidence?
Auteurs : J. Wang [Australie] ; Z K Mcquilten [Australie] ; E M Wood [Australie] ; C. Aubron [France]Source :
- Journal of critical care [ 1557-8615 ] ; 2015.
Descripteurs français
- KwdFr :
- Fasciite nécrosante (traitement médicamenteux), Humains, Immunoglobulines par voie veineuse (usage thérapeutique), Maladie grave, Myasthénie (traitement médicamenteux), Sepsie (traitement médicamenteux), Syndrome de Guillain-Barré (traitement médicamenteux), Syndrome de Stevens-Johnson (traitement médicamenteux).
- MESH :
- traitement médicamenteux : Fasciite nécrosante, Myasthénie, Sepsie, Syndrome de Guillain-Barré, Syndrome de Stevens-Johnson.
- usage thérapeutique : Immunoglobulines par voie veineuse.
- Humains, Maladie grave.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Immunoglobulins, Intravenous.
- drug therapy : Fasciitis, Necrotizing, Guillain-Barre Syndrome, Myasthenia Gravis, Sepsis, Stevens-Johnson Syndrome.
- Critical Illness, Humans.
Abstract
Intravenous immunoglobulin (IVIg) use is growing dramatically internationally due to the increasing numbers of acute and chronic conditions that may benefit from IVIg. Patients with conditions that may benefit from IVIg might require intensive care unit (ICU) admission, supporting the need to review IVIg use in the critical care setting. The most common clinical indications for IVIg in adults that may require ICU admission and are commonly supported under clinical practice guidelines are Guillain-Barré syndrome, myasthenia gravis and Lambert-Eaton myasthenic syndrome, inflammatory myopathies, and primary or secondary immunodeficiency diseases complicated by severe bacterial sepsis. Other emerging indications include necrotizing fasciitis, toxic epidermal necrolysis/Stevens-Johnson syndrome, and toxic shock syndrome. The evidence for IVIg use in sepsis and septic shock remains controversial and insufficient to recommend its routine use. Intravenous immunoglobulin is expensive and also carries risks of adverse effects, including common and benign infusion-related reactions, as well as relatively rare and more serious problems, such as thromboembolic events, renal failure, and aseptic meningitis. In this article, we review the literature on conditions requiring ICU admission and IVIg, and we classify them as supported, emerging, or unsupported indications based on the available evidence and guidelines for clinical use of IVIg.
DOI: 10.1016/j.jcrc.2015.01.022
PubMed: 25702845
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002D36
- to stream PubMed, to step Curation: 002C61
- to stream PubMed, to step Checkpoint: 002C61
- to stream Ncbi, to step Merge: 002274
- to stream Ncbi, to step Curation: 002274
- to stream Ncbi, to step Checkpoint: 002274
- to stream Main, to step Merge: 002C18
- to stream Main, to step Curation: 002C18
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Intravenous immunoglobulin in critically ill adults: When and what is the evidence?</title><author><name sortKey="Wang, J" sort="Wang, J" uniqKey="Wang J" first="J" last="Wang">J. Wang</name><affiliation wicri:level="1"><nlm:affiliation>ANZIC Research Center, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC 3004, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>ANZIC Research Center, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC 3004</wicri:regionArea><wicri:noRegion>VIC 3004</wicri:noRegion></affiliation></author><author><name sortKey="Mcquilten, Z K" sort="Mcquilten, Z K" uniqKey="Mcquilten Z" first="Z K" last="Mcquilten">Z K Mcquilten</name><affiliation wicri:level="1"><nlm:affiliation>ANZIC Research Center, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC 3004, Australia; Transfusion Research Unit, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC 3004, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>ANZIC Research Center, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC 3004, Australia; Transfusion Research Unit, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC 3004</wicri:regionArea><wicri:noRegion>VIC 3004</wicri:noRegion></affiliation></author><author><name sortKey="Wood, E M" sort="Wood, E M" uniqKey="Wood E" first="E M" last="Wood">E M Wood</name><affiliation wicri:level="1"><nlm:affiliation>Transfusion Research Unit, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC 3004, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Transfusion Research Unit, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC 3004</wicri:regionArea><wicri:noRegion>VIC 3004</wicri:noRegion></affiliation></author><author><name sortKey="Aubron, C" sort="Aubron, C" uniqKey="Aubron C" first="C" last="Aubron">C. Aubron</name><affiliation wicri:level="1"><nlm:affiliation>ANZIC Research Center, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC 3004, Australia; Transfusion Research Unit, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC 3004, Australia; Réanimation médicale, Hôpital Universitaire de Brest site de la Cavale Blanche, Université de Bretagne Occidentale, 29200 Brest, France. Electronic address: cecile.aubron@monash.edu.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>ANZIC Research Center, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC 3004, Australia; Transfusion Research Unit, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC 3004, Australia; Réanimation médicale, Hôpital Universitaire de Brest site de la Cavale Blanche, Université de Bretagne Occidentale, 29200 Brest</wicri:regionArea><wicri:noRegion>29200 Brest</wicri:noRegion><wicri:noRegion>29200 Brest</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25702845</idno><idno type="pmid">25702845</idno><idno type="doi">10.1016/j.jcrc.2015.01.022</idno><idno type="wicri:Area/PubMed/Corpus">002D36</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002D36</idno><idno type="wicri:Area/PubMed/Curation">002C61</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002C61</idno><idno type="wicri:Area/PubMed/Checkpoint">002C61</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002C61</idno><idno type="wicri:Area/Ncbi/Merge">002274</idno><idno type="wicri:Area/Ncbi/Curation">002274</idno><idno type="wicri:Area/Ncbi/Checkpoint">002274</idno><idno type="wicri:Area/Main/Merge">002C18</idno><idno type="wicri:Area/Main/Curation">002C18</idno><idno type="wicri:Area/Main/Exploration">002C18</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Intravenous immunoglobulin in critically ill adults: When and what is the evidence?</title><author><name sortKey="Wang, J" sort="Wang, J" uniqKey="Wang J" first="J" last="Wang">J. Wang</name><affiliation wicri:level="1"><nlm:affiliation>ANZIC Research Center, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC 3004, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>ANZIC Research Center, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC 3004</wicri:regionArea><wicri:noRegion>VIC 3004</wicri:noRegion></affiliation></author><author><name sortKey="Mcquilten, Z K" sort="Mcquilten, Z K" uniqKey="Mcquilten Z" first="Z K" last="Mcquilten">Z K Mcquilten</name><affiliation wicri:level="1"><nlm:affiliation>ANZIC Research Center, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC 3004, Australia; Transfusion Research Unit, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC 3004, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>ANZIC Research Center, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC 3004, Australia; Transfusion Research Unit, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC 3004</wicri:regionArea><wicri:noRegion>VIC 3004</wicri:noRegion></affiliation></author><author><name sortKey="Wood, E M" sort="Wood, E M" uniqKey="Wood E" first="E M" last="Wood">E M Wood</name><affiliation wicri:level="1"><nlm:affiliation>Transfusion Research Unit, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC 3004, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Transfusion Research Unit, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC 3004</wicri:regionArea><wicri:noRegion>VIC 3004</wicri:noRegion></affiliation></author><author><name sortKey="Aubron, C" sort="Aubron, C" uniqKey="Aubron C" first="C" last="Aubron">C. Aubron</name><affiliation wicri:level="1"><nlm:affiliation>ANZIC Research Center, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC 3004, Australia; Transfusion Research Unit, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC 3004, Australia; Réanimation médicale, Hôpital Universitaire de Brest site de la Cavale Blanche, Université de Bretagne Occidentale, 29200 Brest, France. Electronic address: cecile.aubron@monash.edu.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>ANZIC Research Center, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC 3004, Australia; Transfusion Research Unit, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC 3004, Australia; Réanimation médicale, Hôpital Universitaire de Brest site de la Cavale Blanche, Université de Bretagne Occidentale, 29200 Brest</wicri:regionArea><wicri:noRegion>29200 Brest</wicri:noRegion><wicri:noRegion>29200 Brest</wicri:noRegion></affiliation></author></analytic><series><title level="j">Journal of critical care</title><idno type="eISSN">1557-8615</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Critical Illness</term><term>Fasciitis, Necrotizing (drug therapy)</term><term>Guillain-Barre Syndrome (drug therapy)</term><term>Humans</term><term>Immunoglobulins, Intravenous (therapeutic use)</term><term>Myasthenia Gravis (drug therapy)</term><term>Sepsis (drug therapy)</term><term>Stevens-Johnson Syndrome (drug therapy)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Fasciite nécrosante (traitement médicamenteux)</term><term>Humains</term><term>Immunoglobulines par voie veineuse (usage thérapeutique)</term><term>Maladie grave</term><term>Myasthénie (traitement médicamenteux)</term><term>Sepsie (traitement médicamenteux)</term><term>Syndrome de Guillain-Barré (traitement médicamenteux)</term><term>Syndrome de Stevens-Johnson (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Immunoglobulins, Intravenous</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Fasciitis, Necrotizing</term><term>Guillain-Barre Syndrome</term><term>Myasthenia Gravis</term><term>Sepsis</term><term>Stevens-Johnson Syndrome</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Fasciite nécrosante</term><term>Myasthénie</term><term>Sepsie</term><term>Syndrome de Guillain-Barré</term><term>Syndrome de Stevens-Johnson</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Immunoglobulines par voie veineuse</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Critical Illness</term><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Maladie grave</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Intravenous immunoglobulin (IVIg) use is growing dramatically internationally due to the increasing numbers of acute and chronic conditions that may benefit from IVIg. Patients with conditions that may benefit from IVIg might require intensive care unit (ICU) admission, supporting the need to review IVIg use in the critical care setting. The most common clinical indications for IVIg in adults that may require ICU admission and are commonly supported under clinical practice guidelines are Guillain-Barré syndrome, myasthenia gravis and Lambert-Eaton myasthenic syndrome, inflammatory myopathies, and primary or secondary immunodeficiency diseases complicated by severe bacterial sepsis. Other emerging indications include necrotizing fasciitis, toxic epidermal necrolysis/Stevens-Johnson syndrome, and toxic shock syndrome. The evidence for IVIg use in sepsis and septic shock remains controversial and insufficient to recommend its routine use. Intravenous immunoglobulin is expensive and also carries risks of adverse effects, including common and benign infusion-related reactions, as well as relatively rare and more serious problems, such as thromboembolic events, renal failure, and aseptic meningitis. In this article, we review the literature on conditions requiring ICU admission and IVIg, and we classify them as supported, emerging, or unsupported indications based on the available evidence and guidelines for clinical use of IVIg.</div></front></TEI><affiliations><list><country><li>Australie</li><li>France</li></country></list><tree><country name="Australie"><noRegion><name sortKey="Wang, J" sort="Wang, J" uniqKey="Wang J" first="J" last="Wang">J. Wang</name></noRegion><name sortKey="Mcquilten, Z K" sort="Mcquilten, Z K" uniqKey="Mcquilten Z" first="Z K" last="Mcquilten">Z K Mcquilten</name><name sortKey="Wood, E M" sort="Wood, E M" uniqKey="Wood E" first="E M" last="Wood">E M Wood</name></country><country name="France"><noRegion><name sortKey="Aubron, C" sort="Aubron, C" uniqKey="Aubron C" first="C" last="Aubron">C. Aubron</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002C18 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002C18 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:25702845
|texte= Intravenous immunoglobulin in critically ill adults: When and what is the evidence?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:25702845" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |